Novo Nordisk, Emisphere Collaborate To Propel Oral GLP-1 Compounds In R&D
This article was originally published in The Pink Sheet Daily
Executive Summary
Emisphere carrier technology may be applied to other compounds as well.
You may also be interested in...
Novo Signs Up Another Oral Insulin Partner, Hedging Its Bets
Novo Nordisk places another oral insulin technology bet with Emisphere; expands partnership with Merrion beyond insulin.
Novo Signs Up Another Oral Insulin Partner, Hedging Its Bets
Novo Nordisk places another oral insulin technology bet with Emisphere; expands partnership with Merrion beyond insulin.
Can Oral GLP-1 Be More than Just Convenient?
Given the collapse of all the inhaled insulin collaborations, many observers are skeptical that the Novo/Emisphere collaboration to create an oral version of Novo's liraglutide GLP-1 -- the drug-delivery company's biggest deal ever -- will work out any better. GLP-1, however, doesn't have all the baggage of insulin therapy, so there is in fact better logic for an oral pill's success. Still, if the program creates merely an oral version of once-a-day liraglutide, with no clinical advantages over its GLP-1 competitors, it will die just as certainly as did inhaled insulin.